gefitinib has been researched along with olaparib in 4 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (olaparib) | Trials (olaparib) | Recent Studies (post-2010) (olaparib) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 1,313 | 172 | 1,258 |
| Protein | Taxonomy | gefitinib (IC50) | olaparib (IC50) |
|---|---|---|---|
| Poly [ADP-ribose] polymerase tankyrase-1 | Homo sapiens (human) | 1.538 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.02 | |
| Cholinesterase | Homo sapiens (human) | 0.0035 | |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | 0.1741 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.02 | |
| Protein mono-ADP-ribosyltransferase PARP6 | Homo sapiens (human) | 1.8 | |
| Protein mono-ADP-ribosyltransferase PARP15 | Homo sapiens (human) | 7.6216 | |
| Protein mono-ADP-ribosyltransferase PARP10 | Homo sapiens (human) | 5.2854 | |
| Protein mono-ADP-ribosyltransferase PARP16 | Homo sapiens (human) | 5.1143 | |
| Poly [ADP-ribose] polymerase tankyrase-2 | Homo sapiens (human) | 2.3349 | |
| Histamine H3 receptor | Cavia porcellus (domestic guinea pig) | 0.001 | |
| Poly [ADP-ribose] polymerase 2 | Homo sapiens (human) | 0.1866 | |
| Protein mono-ADP-ribosyltransferase PARP4 | Homo sapiens (human) | 0.4087 | |
| Protein mono-ADP-ribosyltransferase PARP3 | Homo sapiens (human) | 0.1315 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Goodfellow, E; Huang, S; Jean-Claude, BJ; Schmitt, J; Williams, C | 1 |
| Chen, L; Gu, X; Huo, J; Li, H; Liu, Y; Wang, W; Wang, Y; Wu, C; Zhang, Q; Zheng, M; Zhou, X; Zhou, Y | 1 |
| Arrieta, O; Bosch-Barrera, J; Caro, RB; Dómine, M; Drozdowskyj, A; Garcia-Campelo, R; Granados, ALO; Guirado, M; Insa, A; Karachaliou, N; Lianes, P; Majem, M; Massuti, B; Molina-Vila, MA; Reguart, N; Rodriguez-Abreu, D; Rosell, R; Sala, MÁ; Vázquez-Estevez, S; Verdú, A; Vicente, D | 1 |
1 trial(s) available for gefitinib and olaparib
| Article | Year |
|---|---|
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Goals; Humans; Lung Neoplasms; Mexico; Mutation; Phthalazines; Piperazines; Protein Kinase Inhibitors; Quinazolines; Spain | 2020 |
3 other study(ies) available for gefitinib and olaparib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Design and Synthesis of a Trifunctional Molecular System "Programmed" to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells.
Topics: Cell Line, Tumor; DNA Damage; Down-Regulation; Drug Design; ErbB Receptors; Humans; Male; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Signal Transduction | 2020 |
Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Survival; Drug Design; ErbB Receptors; Gefitinib; Humans; Ligands; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerases; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proteolysis; Recombinant Proteins; Ubiquitin-Protein Ligases | 2021 |